Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced the appointment of experienced oncologist and clinical trial specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer.

Dr Lickliter is a highly experienced and credentialed clinician with extensive experience in running and overseeing clinical trials. He trained as a medical oncologist in Australia and at the University of Minnesota and has extensive experience in designing and implementing early-phase patient and healthy-volunteer clinical trials.

Dr Lickliter has been acting in the role of clinical adviser to Amplia since 2021, chairing the Company’s clinical trial safety committee and advising on the Phase 1 trial of narmafotinib in healthy volunteers and on the ongoing ACCENT trial.

Amplia CEO and MD Dr Chris Burns commented:  
 
“We are delighted that Dr Lickliter is joining the team at Amplia. It’s an exciting time for the Company as we near important data readouts for the ongoing ACCENT Phase 2a trial and with the FOLFIRINOX combination Phase 1b/2a trial shortly to start. Jason’s involvement and contributions as CMO will be critical to help guide our ongoing clinical activities.”

Amplia Appoints Dr Jason Lickliter as Chief Medical Officer  